Plerixafor Improves Immunotherapy Response in Mouse Model of Breast Cancer

Plerixafor Improves Immunotherapy Response in Mouse Model of Breast Cancer
Plerixafor — approved for the treatment of lymphoma and multiple myeloma —  decreases tumor fibrosis and improves immunotherapy response in a mouse model of metastatic breast cancer, a study finds. The study, "Blocking CXCR4 alleviates desmoplasia, increases T-lymphocyte infiltration, and improves immunotherapy in metastatic breast cancer," was published in PNAS. The researchers found that fibrosis — the excessive growth of connective tissue inside tumors — prevented cancer-fighting T-cells from entering tumors and largely impaired immune checkpoint inhibitors from effectively eliminating metastatic breast cancer. Primary breast cancer tumors contain a dense core of fibrotic tissue that has been shown in other types of tumors to suppress the activity of immune cells against cancer cells, rendering current cancer immunotherapies ineffective. Once cancer has metastasized, the composition of tumor masses and their interaction with the immune system remain unclear. One aspect that is clear, though, is that metastatic breast cancer is extremely resistant to current cancer therapies, which is linked to poor survival outcomes. "Improving the survival of pa
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.